[HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy]

Area of Science:

• Immunology
• Virology
• Hepatology

Context:

• Hepatitis B virus (HBV) infection poses a significant global health challenge.
• Lamivudine therapy can achieve viral suppression but relapse is common upon cessation.
• The role of host immune response in preventing viral relapse requires further elucidation.

Purpose:

• To compare the frequency and functional capacity of HBV-specific CD8+ T cells in patients with sustained HBeAg seroconversion versus those who relapse after lamivudine therapy.
• To investigate the association between HBV-specific CD8+ T cell responses and sustained virologic control.

Summary:

• This study analyzed HBV-specific CD8+ T cells in 14 HLA-A2 patients who achieved HBeAg seroconversion post-lamivudine treatment.
• Patients with sustained HBeAg response exhibited significantly higher frequencies of HBV core 18-27-specific CD8+ T cells (Tc 18-27) compared to relapsed patients.
• Sustained responders also showed a more vigorous expansion of these T cells upon viral peptide stimulation.

Impact:

• The findings highlight the critical role of a robust HBV-specific CD8+ T cell response in achieving and maintaining long-term viral suppression after lamivudine treatment.
• This suggests that immune status, particularly CD8+ T cell function, could be a predictive marker for treatment outcomes in chronic hepatitis B.
• Understanding these immune mechanisms may pave the way for novel therapeutic strategies aimed at enhancing host immunity for durable HBV control.